Serina Therapeutics Stock Current Asset
| SER Stock | 4.79 0.64 15.42% |
Serina Therapeutics fundamentals help investors to digest information that contributes to Serina Therapeutics' financial success or failures. It also enables traders to predict the movement of Serina Stock. The fundamental analysis module provides a way to measure Serina Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Serina Therapeutics stock.
As of 12/18/2024, Non Current Assets Total is likely to grow to about 11.8 M. Also, Other Current Assets is likely to grow to about 504.8 K. Serina | Current Asset |
Serina Therapeutics Company Current Asset Analysis
Serina Therapeutics' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Serina Current Asset Historical Pattern
Today, most investors in Serina Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Serina Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Serina Therapeutics current asset as a starting point in their analysis.
Serina Therapeutics Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Serina Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Serina Therapeutics has a Current Asset of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current asset for all United States stocks is 100.0% higher than that of the company.
Serina Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Serina Therapeutics' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Serina Therapeutics could also be used in its relative valuation, which is a method of valuing Serina Therapeutics by comparing valuation metrics of similar companies.Serina Therapeutics is currently under evaluation in current asset category among its peers.
Serina Fundamentals
| Return On Asset | -0.45 | ||||
| Profit Margin | (2.21) % | ||||
| Operating Margin | (75.80) % | ||||
| Current Valuation | 62.84 M | ||||
| Shares Outstanding | 8.88 M | ||||
| Shares Owned By Insiders | 58.14 % | ||||
| Shares Owned By Institutions | 2.30 % | ||||
| Number Of Shares Shorted | 27.52 K | ||||
| Price To Sales | 18.03 X | ||||
| Revenue | 142 K | ||||
| EBITDA | (9.78 M) | ||||
| Net Income | (14.8 M) | ||||
| Total Debt | 4.37 M | ||||
| Book Value Per Share | (1.86) X | ||||
| Cash Flow From Operations | (7.8 M) | ||||
| Short Ratio | 1.73 X | ||||
| Earnings Per Share | 0.14 X | ||||
| Market Capitalization | 57.2 M | ||||
| Total Asset | 11.96 M | ||||
| Retained Earnings | (131.01 M) | ||||
| Working Capital | 110.89 K | ||||
| Net Asset | 11.96 M |
About Serina Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Serina Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Serina Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Serina Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Serina Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Serina Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Serina Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Serina Stock
Moving against Serina Stock
| 0.73 | GILD | Gilead Sciences | PairCorr |
| 0.71 | BMY | Bristol Myers Squibb | PairCorr |
| 0.62 | DYAI | Dyadic International | PairCorr |
| 0.53 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
The ability to find closely correlated positions to Serina Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Serina Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Serina Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Serina Therapeutics to buy it.
The correlation of Serina Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Serina Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Serina Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Serina Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Serina Stock Analysis
When running Serina Therapeutics' price analysis, check to measure Serina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Serina Therapeutics is operating at the current time. Most of Serina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Serina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Serina Therapeutics' price. Additionally, you may evaluate how the addition of Serina Therapeutics to your portfolios can decrease your overall portfolio volatility.